Commentary: Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
The treatment of patients with psoriasis has been challenged by the COVID 19 pandemic. In March 2020, with a lack of data allowing an evidence-based approach, IPC formulated a statementurging physicians to discontinue immunosuppressive treatments in patients with active COVID-19 disease. For psoriasis patients with no signs or symptoms of COVID-19, decisions about continuing treatment needed to be taken on a case by case basis, balancing risk with benefit.
I would like to draw your attention to a publication by Paulo Gisondi from Verona on the risk of hospitalization and death from COVID-19 in psoriatic patients receiving biological treatments (980 patients) and renal transplant recipients on immunosuppressive treatment (247 patients).
No psoriatic patients were hospitalized or died for the reason of COVID 19 and only one kidney transplant recipient died. In the general population of Verona, 0.28% of the COVID-19 patients were hospitalized or died. The average age of the patients with psoriasis and renal transplant recipients was 56 and 57 years respectively. 39 % of the psoriasis patients were obese and 12% had diabetes and cardiovascular disease. The authors indicated several limitations of the study. Nevertheless, the study provides important early information.
At present dermatologists are collecting information in COVID registries. IPC is pleased to be a partner on thePsoProtect registryfor psoriasis and COVID-19 positive patients. Please consider submitting a case or cases to the registry as it is of utmost importance that we collect the data from patients with psoriasis suffering from COVID-19.
Disclaimer: Views expressed in this commentary are those of the author and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Commentary: Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Peter van de Kerkhof, MD, PhD
IPC Chief Medical Officer
The Netherlands
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085.
COMMENTARY
The treatment of patients with psoriasis has been challenged by the COVID 19 pandemic. In March 2020, with a lack of data allowing an evidence-based approach, IPC formulated a statement urging physicians to discontinue immunosuppressive treatments in patients with active COVID-19 disease. For psoriasis patients with no signs or symptoms of COVID-19, decisions about continuing treatment needed to be taken on a case by case basis, balancing risk with benefit.
I would like to draw your attention to a publication by Paulo Gisondi from Verona on the risk of hospitalization and death from COVID-19 in psoriatic patients receiving biological treatments (980 patients) and renal transplant recipients on immunosuppressive treatment (247 patients).
No psoriatic patients were hospitalized or died for the reason of COVID 19 and only one kidney transplant recipient died. In the general population of Verona, 0.28% of the COVID-19 patients were hospitalized or died. The average age of the patients with psoriasis and renal transplant recipients was 56 and 57 years respectively. 39 % of the psoriasis patients were obese and 12% had diabetes and cardiovascular disease. The authors indicated several limitations of the study. Nevertheless, the study provides important early information.
At present dermatologists are collecting information in COVID registries. IPC is pleased to be a partner on the PsoProtect registry for psoriasis and COVID-19 positive patients. Please consider submitting a case or cases to the registry as it is of utmost importance that we collect the data from patients with psoriasis suffering from COVID-19.
Disclaimer: Views expressed in this commentary are those of the author and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.
Categories
Tags
Recent Posts
IPC Appoints New President for 2023
Focus on Psoriasis: A Report from the 2022 IPC Think Tank – Miami
Meet Our 2022 Volunteers of the Year
Also Read
Prioritizing the Patient Perspective in Psoriasis Care and Communications
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Revised IPC Statement on COVID-19
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
IPC Partners with Scientific Education Support to Create New Psoriasis and Psoriatic Arthritis Hub
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
Subscribe to the IPC Newsletter